• DNA X filed an amended Form 8-K to update disclosures on its Series B Preferred Stock financing and related charter changes.
• The filing reported the July 8 sale of 929,864 Series B Preferred shares for USD 2.5 million cash, also canceling USD 3.1 million under a convertible promissory note.
• The company expects to issue the remaining 416,667 subscribed shares by Aug. 14.
• It reported estimated stockholders’ equity of about USD 3.8 million as of July 9, above Nasdaq’s USD 2.5 million continued-listing threshold.
• Nasdaq’s formal compliance determination remained pending.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DNA X Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032680), on July 09, 2026, and is solely responsible for the information contained therein.